FCMV
SYRE icon

Foresite Capital Management VI’s Spyre Therapeutics SYRE Stock Holding History

Foresite Capital Management VI’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-70,000
Closed -$1.05M – 18
2025
Q2 		$1.05M Buy
+70,000
New +$1.04M 0.59% 18

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Foresite Capital Management VI's SYRE Position: Q3 2025 in Review

Foresite Capital Management VI sold out of Spyre Therapeutics (SYRE) in Q3 2025, closing a stake of 70,000 shares — an estimated $1.05M sold.

Foresite Capital Management VI first reported a position in SYRE in Q2 2025 and held it in 1 quarter. The position peaked at $1.05M in Q2 2025. 137 funds tracked by Wall St. Rank hold SYRE as of Q3 2025.

  • Foresite Capital Management VI reported no remaining Spyre Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Foresite Capital Management VI sold 70,000 Spyre Therapeutics shares in Q3 2025, an estimated $1.05M.
  • Foresite Capital Management VI first reported a position in Spyre Therapeutics in Q2 2025 and held it in 1 quarter.
  • Foresite Capital Management VI's Spyre Therapeutics position peaked at $1.05M in Q2 2025.
  • 137 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2025.

Based on Foresite Capital Management VI's 13F filing for Q3 2025, filed 14 Nov 2025.